Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs Tocilizumab in Behçet's Uveitis
NCT05874505Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2023
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 2, randomised trial of tocilizumab in Behçet's disease (BD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients with complete remission of ocular involvement at 16 weeks. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT05874505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874505.